A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants

Inclusion Criteria:

* Male 18 years of age or older
* Participant with histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
* Participant with documented metastatic prostate cancer
* Participant with documented castration resistance with progression of prostate cancer on androgen deprivation therapy (ADT)
* Participant who will be initiated on either abiraterone acetate or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that is asymptomatic or mildly symptomatic (per physician's evaluation) after failure of ADT at the time of treatment initiation
* Participants who signed a participation agreement or Informed consent form (ICF) per local regulations
* The treatment decision (abiraterone acetate or enzalutamide) by the treating physician must have been taken before enrollment into the study
* Baseline patient-reported outcomes (PROs) must be captured before the first administration of abiraterone acetate or enzalutamide.

Exclusion Criteria:

* Patient who has received any chemotherapy/cytotoxic agent to treat their mCRPC before abiraterone acetate or enzalutamide initiation; or ; treat their metastatic hormone-sensitive prostate cancer (mHSPC) \<12 months prior to abiraterone acetate or enzalutamide initiation.
* Participant who is not capable of completing a patient survey
* Participant who has received or is currently receiving abiraterone acetate or enzalutamide
* Patient receiving an investigational treatment for prostate cancer of any kind before or at the time of initiation of abiraterone acetate or enzalutamide
* Participant who is currently included in other observational studies with abiraterone acetate sponsored by Janssen